Designing and structure evaluation of multi-epitope vaccine against ETEC and EHEC, an in silico approach.
Diarrheal diseases represent a major health problem in developing countries. Several viruses and bacterial agents, such as Enterotoxigenic Escherichia coli (ETEC) and Enterohemorrhagic Escherichia coli (EHEC) are responsible for human enteric infections. In humans, EHEC infections result in bloody or non-bloody diarrhea, which may be complicated by haemorrhagic colitis and haemolytic uraemic syndrome (HUS). Infection by ETEC is accompanied by a non inflammatory watery diarrhea. E. coli follows a common strategy of infection: colonization on a mucosal site, evasion of host defenses, multiplication, and host damage. Intimin, Stx, Lt and Cfa proteins are the virulence factors expressed by these strains. Antibiotic treatment is generally not recommended for most cases of diarrhea, since antibiotic usage may lead to antibiotic resistance in ETEC and may also change the intestinal flora. We hypothesized that the chimeric forms of these effectors as vaccine candidates would reduce the colonization of bacteria. This study is based on an in silico analysis of chimeric protein structure and its stability and solubility. The secondary and tertiary structures of selected domains were also predicted. Moreover, T and B cell epitopes were mapped. Protein structure Prediction showed that each domain of antigen was separated completely also stable for recombinant expression. We believe that this chimeric vaccine candidate is effective for prevention of bacteria caused diarrheal diseases.
Department of Agricultural Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Shahrak-e-Pajoohesh, 15th Km, Tehran -Karaj Highway, P.O. Box: 14965-161, Tehran, Iran. salman@nigeb.ac.ir.
Fatemeh S
FS
Jeshvaghani
Ahmad K
AK
Rahjerdi
Jafar
J
Amani
Iman
I
Rad
Mahyat
M
Jafari
Ali H
AH
Salmanian
D003198:Computer Simulation; D003967:Diarrhea / Q000382:microbiology; D054324:Enterohemorrhagic Escherichia coli / Q000276:immunology*; D054307:Enterotoxigenic Escherichia coli / Q000276:immunology*; D018985:Epitopes, B-Lymphocyte / Q000737:chemistry* / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry* / Q000276:immunology; D004927:Escherichia coli Infections / Q000382:microbiology / Q000517:prevention & control; D029968:Escherichia coli Proteins / Q000737:chemistry / Q000276:immunology; D022361:Escherichia coli Vaccines / Q000737:chemistry* / Q000276:immunology; D006801:Humans; D008958:Models, Molecular; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000737:chemistry / Q000276:immunology; D037521:Virulence Factors / Q000737:chemistry* / Q000276:immunology
D018985:Epitopes, B-Lymphocyte; D018984:Epitopes, T-Lymphocyte; D029968:Escherichia coli Proteins; D022361:Escherichia coli Vaccines; D011994:Recombinant Proteins; D037521:Virulence Factors